Evidence map›Paper›PMID 38128698›Full record

ArticleNew biotechnology2024

Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein.

Xiaofeng Li, Liudmila Kulakova, Kezzia Jones, Eric A Toth, Marina Kirkland Mitchell, Qiana Mendez, Michael P Weiner, Thomas R Fuerst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaofeng LiAbbratech Inc., 25 Business Park Drive, Suite C, Branford, CT 06405, USA. Electronic address: xli@abbratech.com.
Liudmila KulakovaInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Kezzia JonesAbbratech Inc., 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Eric A TothInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Marina Kirkland MitchellAbbratech Inc., 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Qiana MendezAbbratech Inc., 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Michael P WeinerAbbratech Inc., 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Thomas R FuerstInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.

Funding

Platform for the High Throughput Generation and Validation of Affinity ReagentsR44GM148998 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2023 to 2024
$2.2M
Structure-guided neutralizing antibodies developed using EpiVolve technologyR44AI177126 · NIAID · ABBRATECH, INC. · PI LI, XIAOFENG · 2023 to 2024
$1.3M
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. I. survey of existing antibodies, and II. development of method improvementsR43GM146473 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2022 to 2022
$339k
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategyR43GM149009 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2023 to 2023
$295k
NIAID NIH HHS R44 AI177126NIGMS NIH HHS R43 GM146473NIGMS NIH HHS R43 GM149009NIGMS NIH HHS R44 GM148998
6 · The paper itself

Abstract

'Epivolve' (epitope evolution) is an innovative paratope-evolving technology using a haptenated peptide or protein immunogen as a means of directing the in vivo immune response to specifically targeted sites at a one amino acid residue resolution. Guided by protein structural analysis, Epivolve technology was tested to develop site-directed neutralizing antibodies (nAbs) in a systematic fashion against the SARS-CoV-2 Receptor Binding Domain (RBD). Thirteen solvent-exposed sites covering the ACE2 receptor-binding interface were targeted. Immunogens composed of each targeted site were used to immunize rabbits in separate cohorts. In vivo site-directed immune responses against all 13 targets were demonstrated by B cell secreted IgG and recombinant IgG testing. One site, SL13 (Y505) which mutates from tyrosine to histidine in the SARS-CoV-2 Omicron variant, was chosen as a proof-of-concept (PoC) model for further functional monoclonal antibody development. Epivolve technology demonstrated the capabilities of generating pan-variant antibodies and nAbs against the SARS-CoV-2 primary strain and the Omicron variant.

Indexed as

Antibodies, NeutralizingCOVID-19AnimalsHumansImmunoglobulin GRabbitsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2EpivolveImmunizationNeutralizing antibodyPan-variant antibodyProtein structureSARS-CoV-2Site-directed antibodySpike protein

Identifiers

PMID38128698
PMCPMC10954356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.